SEC Form 4 filed by Chief Commercial Officer Le Goff Corinne

$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $VTRS alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Le Goff Corinne

(Last) (First) (Middle)
1000 MYLAN BOULEVARD

(Street)
CANONSBURG PA 15317

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Viatris Inc [ VTRS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 03/06/2025 A 132,493 (1) (1) Common Stock 132,493 $0 132,493 D
Explanation of Responses:
1. Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 44,165 of the RSUs granted on March 6, 2025 will vest on March 6, 2026 and 44,164 will vest on each of March 6, 2027 and March 6, 2028.
/s/ Kevin Macikowski, by power of attorney 03/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $VTRS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VTRS

DatePrice TargetRatingAnalyst
7/19/2024$15.00Buy
Jefferies
10/23/2023$13.00 → $9.00Neutral → Underperform
BofA Securities
6/23/2023$11.00Equal Weight → Underweight
Barclays
4/24/2023$11.00Overweight → Equal Weight
Barclays
2/17/2023$16.00 → $14.00Outperform → Market Perform
BMO Capital Markets
1/27/2023$13.00 → $15.00Hold → Buy
Jefferies
11/10/2022$9.00 → $12.00Sell → Neutral
UBS
11/8/2022$10.00Underweight → Neutral
Piper Sandler
More analyst ratings

$VTRS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims

    PITTSBURGH, April 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) (the "Company") today announced it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries. While the Company's presence in the U.S. opioids market is very small, the Company has agreed to this settlement to provide closure on these matters. This settlement is in no way an admission of wrongdoing or liability. Under the agreed upon framework, depending on the level of participation in the settle

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris to Report First Quarter 2025 Financial Results on May 8, 2025

    PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthc

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris to Present at the Barclays 27th Annual Global Healthcare Conference

    PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET. A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcar

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VTRS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VTRS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$VTRS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VTRS
SEC Filings

See more

$VTRS
Leadership Updates

Live Leadership Updates

See more
  • Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

    PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris Appoints Corinne Le Goff as Chief Commercial Officer

    PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer

    Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH, Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. Current Viatris CFO Sanjeev Narula, who h

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VTRS
Financials

Live finance-specific insights

See more
  • Viatris to Report First Quarter 2025 Financial Results on May 8, 2025

    PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthc

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance

    PITTSBURGH, Feb. 27, 2025 /PRNewswire/ --  Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1]Reports 2024 Total Revenues of $14.7 Billion, U.S. GAAP Net Loss of $(634) Million, Adjusted EBITDA of $4.7 Billion, U.S. GAAP Diluted EPS Loss of $(0.53) per Share, Adjusted EPS of $2.65 per Share, U.S. GAAP Net Cash Provided by Operating Activities of $2.3 Billion, and Free Cash Flow of $2.0 Billion Including ~$650 Million of Transaction-Related CostsDelivers Strong New Product Revenues of $582 Million in 2024Returns $825 Million in Capital to Shareholders and Repays $3.7 Billion of Debt in 2024An

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend

    PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistic

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VTRS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more